The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

Bullish option flow detected in BridgeBio (BBIO) Pharma with 2,983 calls trading, 1.0x expected, and implied vol increasing over 2 points to 132.22%. Dec-24 30 calls and Dec-24 35 calls are the ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...